- Previous Close
0.5900 - Open
0.5900 - Bid 0.5900 x --
- Ask 0.6250 x --
- Day's Range
0.5900 - 0.5900 - 52 Week Range
0.5450 - 0.8350 - Volume
3,000 - Avg. Volume
98 - Market Cap (intraday)
3.811B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
8.43 - EPS (TTM)
0.0700 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield 0.04 (6.34%)
- Ex-Dividend Date May 28, 2025
- 1y Target Est
--
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and v, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. It provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
www.crpharm.com72,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 640.F
View MorePerformance Overview: 640.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 640.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 640.F
View MoreValuation Measures
Market Cap
3.81B
Enterprise Value
6.84B
Trailing P/E
8.95
Forward P/E
7.56
PEG Ratio (5yr expected)
1.04
Price/Sales (ttm)
0.12
Price/Book (mrq)
0.62
Enterprise Value/Revenue
0.21
Enterprise Value/EBITDA
4.16
Financial Highlights
Profitability and Income Statement
Profit Margin
1.30%
Return on Assets (ttm)
2.97%
Return on Equity (ttm)
8.80%
Revenue (ttm)
257.67B
Net Income Avi to Common (ttm)
3.33B
Diluted EPS (ttm)
0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.42B
Total Debt/Equity (mrq)
70.35%
Levered Free Cash Flow (ttm)
--